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Antibiotic resistance in the opportunistic pathogen Pseudomonas aeruginosa is partly caused by bioﬁlms
forming a physical barrier to antibiotic penetration. Here we focused on modifying tetravalent
glycopeptide dendrimer ligands of P. aeruginosa lectins LecB or LecA to increase their bioﬁlm inhibition
activity. First heteroglycoclusters were investigated displaying one pair each of LecB speciﬁc fucosyl
groups and LecA speciﬁc galactosyl groups and binding simultaneously to both lectins, one of which
gave the ﬁrst fully resolved crystal structure of a peptide dendrimer as LecB complex providing
a structural model for dendrimer–lectin interactions (PDB 5D2A). Bioﬁlm inhibition was increased by
introducing additional cationic residues in these dendrimers but resulted in bactericidal eﬀects similar to
those of non-glycosylated polycationic antimicrobial peptide dendrimers. In a second approach
dendrimers displaying four copies of the natural LecB ligand Lewisa were prepared leading to slightly
stronger LecB binding and bioﬁlm inhibition. Finally synergistic application of a LecB speciﬁc non-
bactericidal antibioﬁlm dendrimer with the antibiotic tobramycin at sub-inhibitory concentrations of both
compounds allowed eﬀective bioﬁlm inhibition and dispersal.Introduction
The appearance of widespread antibiotic resistance in patho-
genic bacteria is a global public health threat. One approach to
overcome antibiotic resistance focuses on preventing the
formation of biolms, by which bacteria escape antibiotics by
forming a physical barrier to their penetration. Biolm inhibi-
tors should not be toxic by themselves to avoid the possibility of
an evolutionary pressure towards resistance.1 One potential
application of this approach concerns Pseudomonas aeruginosa,
a gram negative bacterium causing lethal airway infections in
immunocompromised and cystic brosis patients by forming
antibiotic resistant biolms.2 It has been shown that two P.
aeruginosa lectins, namely LecA binding specically to galacto-
sides, and LecB binding specically to fucosides, are implicated, University of Berne, Freiestrasse 3, 3012
nd@dcb.unibe.ch
e Tecnologico, Universita' degli Studi di
Sesto Fiorentino, Firenze, Italy
e´cules Ve´ge´tales, UPR5301, CNRS and
imie, F38041 Grenoble, France
(ESI) available: Details of carbohydrate
endrimer synthesis, ITC plots, biolm
termination, cell viability assays and
phic data table for 5D2A. See DOI:in biolm formation by this bacterium,3–7 as evidenced by the
impaired biolm formation in deletion mutants8,9 and the
successful treatment of P. aeruginosa infections with lectin-
binding saccharide solutions.10–12
Recently we reported glycopeptide dendrimers targeting
these lectins and capable of both biolm inhibition and
dispersal of already established biolms. The rst dendrimer
FD2, a tetravalent fucosylated dendrimer with sequence (fucose-
a-CH2CO-Lys-Pro-Leu)4(Lys-Phe-Lys-Ile)2Lys-His-Ile-NH2 (Lys ¼
branching lysine residue), was initially identied in a glyco-
peptide dendrimer combinatorial library13,14 by screening for
binding to a fucose specic plant lectin,15–18 and showed tight
binding to LecB.19–21 Two additional dendrimers were subse-
quently developed by appending galactosyl groups to the
peptide backbone of FD2, yielding tight binding LecA ligands
GalAG2 and GalBG2 (Scheme 1).22 These glycopeptide den-
drimers belong to the very few LecA or LecB ligands thus far
reported to display P. aeruginosa biolm inhibition properties,23
among a large number of related multivalent lectin ligands.24–30
Structure–activity relationship studies with FD2 and GalAG2
showed that multivalency and the nature of the amino acid
sequence were critical for biological activity, however in both
cases no signicant activity increase was achieved beyond the
level of a minimal biolm inhibitory concentration (MBIC)
value of 20 mM, calling for alternative approaches for activity
improvement.20,21,31–34This journal is © The Royal Society of Chemistry 2016
Scheme 1 Structure and synthesis of glycopeptide dendrimers. Conditions: SPPS: (a) Fmoc deprotection with piperidine/NMP 1 : 4 (v/v), 20min;
alloc deprotection: Pd(PPh3)4, PhSiH3, CH2Cl2; amino acid coupling (3 eq. Fmoc-aa-OH, 3 eq. PyBOP, 5 eq. DIEA in NMP), 2–4 hours; carbo-
hydrate coupling: 4 eq. carbohydrate building block, 3 eq. HATU, 5 eq. DIPEA in NMP, overnight; (b) deacetylation: MeOH/25%NH3/H2O (8 : 1 : 1,
v/v/v); (c) cleavage: TFA/TIS/H2O (95 : 2.5 : 2.5, v/v/v) or TFA/TIS/H2O/1,2-ethandithiol (92.5/2.5/2.5/2.5) for Cys containing peptide; (d) RP-
HPLC puriﬁcation, ClAc ligation: ClAcG1 (1 eq.), Het1G1-Cys (3 eq.), KI (20 eq.) DIPEA (55 eq.) in NMP/H2O (1 : 1, v/v), RT, overnight under Argon
atmosphere. One letter codes for L-amino acids, x ¼ –CH2–CO–, wobbly bonds mark the side-chain lysine connectivity. The color codes are
used to diﬀerentiate G0 (red), G1 (green) and G2 (black/blue) branches.
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View Article OnlineHerein we report the extension of our search towards more
potent biolm inhibitors through further synthetic variations
and activity combination approaches. The multivalent chlor-
oacetyl cysteine thioether (ClAc) ligation35 was used as an eﬃ-
cient method to access heteroglycoclusters such as Het1G2
targeting both LecA and LecB (Scheme 1). One of the hetero-
glycoclusters provided the rst fully resolved crystal structure of
a peptide dendrimer as a LecB complex and a structural model
for dendrimer–LecB interactions. Heteroglycoclusters incorpo-
rating cationic residues showed enhanced biolm inhibition,
however the activity reected a bactericidal eﬀect similar to that
of membrane disrupting polycationic dendrimers.36 In a second
approach LecB targeting glycopeptide dendrimers were inves-
tigated displaying analogs of the Lewisa antigen, which is theThis journal is © The Royal Society of Chemistry 2016probable natural LecB ligand,37 resulting in stronger LecB
binding but only a small increase in biolm inhibition. Finally
synergistic application of the LecB specic non-bactericidal
antibiolm dendrimer FD2 with the antibiotic tobramycin at
sub-inhibitory concentrations of both compounds allowed
eﬀective biolm inhibition and dispersal.
Results and discussion
Synthesis and lectin binding of heteroglycoclusters targeting
LecA and LecB
Initial biolm inhibition experiments using the LecB specic
dendrimer FD2 and the LecA specic dendrimer GalAG2
simultaneously showed simple additive eﬀects between bothChem. Sci., 2016, 7, 166–182 | 167
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View Article Onlinedendrimers (see ESI Fig. S109†). Heteroglycocluster analogs of
these dendrimers displaying fucosyl and galactosyl groups were
prepared to test if a compound targeting both lectins might
show enhanced activity compared to the co-application. Due to
diﬃculties in obtaining 8-fold glycosylated G3 peptide den-
drimers we focused on the preparation of 4-fold glycosylated G2
peptide dendrimers carrying one pair each of fucosyl and
galactosyl groups, which should enable binding to LecB
respectively LecA by means of a chelate binding mode on two
adjacent carbohydrate binding sites of the same lectin
tetramer.33,38
The synthesis of G2 glycoclusters was carried out by ClAc
ligation between the bis-chloroacetylated G1 dendrimer ClAcG1
and bis-glycosylated G1 peptide dendrimers with a cysteine
residue at their core (Scheme 1).35 This convergent synthesis
was more economical than the previously used direct SPPS of
G2 glycopeptide dendrimers, for which the four-fold glycoside
coupling consumed large amounts of carbohydrate building
block.34 The method was used to prepare analogs of FD2,
GalAG2 and GalBG2, namely FD2x, GalAG2x and GalBG2x, byTable 1 Sequence and synthesis of G2 glycopeptide dendrimers
Compound Sequencea
FD0 cFuc-KPL
GalAG0 GalA-KPL
GalBG0 GalB-KPL
FD1 (cFuc-KPL)2KFKI
GalAG1 (GalA-KPL)2KFKI
GalBG1 (GalB-KPL)2KFKI
FD1-Cys (cFuc-KPL)2KFC
GalAG1-Cys (GalA-KPL)2KFC
GalBG1-Cys (GalB-KPL)2KFC
Het1G1-Cys cFuc-KPLK(GalA-KPL)FC
Het2G1-Cys GalA-KPLK(cFuc-KPL)FC
Het3G1-Cys cFuc-KPLK(GalB-KPL)FC
Het4G1-Cys GalB-KPLK(cFuc-KPL)FC
Het5G1-Cys cFuc-KKLK(GalA-KKL)FC
Het6G1-Cys GalA-KKLK(cFuc-KKL)FC
Het7G1-Cys cFuc-KKLK(GalB-KKL)FC
Het8G1-Cys GalB-KKLK(cFuc-KKL)FC
ClAcG1 (ClAc-KI)2KHI
FD2 (cFuc-KPL)4(KFKI)2KHI
GalAG2 (GalA-KPL)4(KFKI)2KHI
GalBG2 (GalB-KPL)4(KFKI)2KHI
FD2x (cFuc-KPL)4(KFCxKI)2KHI
GalAG2x (GalA-KPL)4(KFCxKI)2KHI
GalBG2x (GalB-KPL)4(KFCxKI)2KHI
Het1G2 (cFuc-KPLK(GalA-KPL)FCxKI)2KHI
Het2G2 (GalA-KPLK(cFuc-KPL)FCxKI)2KHI
Het3G2 (cFuc-KPLK(GalB-KPL)FCxKI)2KHI
Het4G2 (GalB-KPLK(cFuc-KPL)FCxKI)2KHI
Het5G2 (cFuc-KKLK(GalA-KKL)FCxKI)2KHI
Het6G2 (GalA-KKLK(cFuc-KKL)FCxKI)2KHI
Het7G2 (cFuc-KKLK(GalB-KKL)FCxKI)2KHI
Het8G2 (GalB-KKLK(cFuc-KKL)FCxKI)2KHI
a One letter code for amino acids. Branching Lys in italics. GalB is carboxpr
fucoside. x ¼ –CH2CO–. The peptide C-terminus is carboxamide –CONH
between line notation and structure. b MS calc. for [M + H]+/MS obs. dete
aer SPPS or chloroacetyl cysteine (ClAc) ligation. d From ref. 15. e From
168 | Chem. Sci., 2016, 7, 166–182ligation of the G1 intermediates FD1-Cys, GalAG1-Cys and
GalBG1-Cys to the bis-chloroacetylated G1 dendrimer ClAcG1.
Heteroglycoclusters were prepared by the same ligation
approach using bis-glycosylated G1 dendrimers bearing
a diﬀerent carbohydrate on each branch, which were obtained
using an alloc protected lysine branching residue allowing
sequential growth of each G1 branch. All combinations of a-L-
fucosylacetic acid (cFuc) with 4-(b-D-galactosyloxy)-benzoic acid
(GalA) or 3-(b-D-thiogalactosyl)-propionic acid (GalB) on the
main chain tripeptide versus side chain tripeptide were realized,
yielding intermediates Het1G1-Cys to Het4G1-Cys and G2 het-
eroglycoclusters Het1G2–Het4G2. The same synthesis was
carried out using the tripeptide Lys-Lys-Leu instead of Lys-Pro-
Leu in the outer branch of the peptide dendrimer to obtain
more polycationic glycoclusters combining lectin binding with
a membrane directed antimicrobial eﬀect, yielding G1 inter-
mediates Het5G1–Het8G1 and the G2 ligation products
Het5G2–Het8G2 (Table 1).
The binding aﬃnities of the diﬀerent compounds to P. aer-
uginosa lectins LecB and LecA was investigated by isothermalMS calc./obs.b Yieldc (mg/%)
544.34/544.33 19.5/29d
638.33/638.2 20.9/55e
606.31/606.2 11/30e
1586.97/1586.98 123.3/63d
1774.98/1774.8 45.7/43e
1710.93/1710.8 39.5/39e
1448.81/1447.80 33.5/18
1636.82/1637.82 79/39
1572.77/1573.78 29.5/15
1542.82/1543.81 63/33
1542.82/1543.81 50/26
1510.79/1510.79 52/28
1510.79/1510.78 50/26
1604.90/1604.90 30/15
1604.90/1604.90 32.5/16
1572.88/1572.88 66/34
1572.88/1572.87 52/26
1030.58/1029.57 89/70
3534.16/3534.16 31/8d
3909.17/3911 18.2/7e
3783.07/3783 22.1/10e
3854.22/3854.23 7.9/70
4230.24/4231.24 2.9/24
4102.15/4103.15 3.8/32
4042.23/4043.23 10.3/88
4042.23/4042.23 9.3/79
3978.19/3979.18 3.6/31
3978.19/3978.19 7.3/63
4166.40/4166.40 6.6/54
4166.40/4166.40 7.1/59
4102.36/4102.36 11.1/69
4102.36/4102.36 10.3/57
opyl b-thiogalactoside. GalA is 4-carboxyphenyl b-galactoside. cFuc is a-c-
2. See structural formula of Het1G2 in Scheme 1 for correspondence
rmined by ESI+. c Yields are reported for the RP-HPLC puried product
ref. 22.
This journal is © The Royal Society of Chemistry 2016
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View Article Onlinetitration calorimetry (ITC). Binding to the fucose specic lectin
LecB ranged between KD ¼ 430 nM for the reference carbohy-
drate methyl-a-L-fucoside39 and KD ¼ 66 nM for the tetravalent
dendrimer FD2 (Table 2). At the level of the monovalent ligands,
the c-fucosylated tripeptide FD0 was a poorer ligand than
methyl-a-L-fucoside, while the monovalent Het1G1-Cys and
Het2G1-Cys bound even less tightly and showed a too high n
value, which might indicate aggregation via disulde bond
formation and/or intermolecular b-sheets as observed in the
crystal structure (see below), possibly hindering lectin access for
part of the glycosyl groups. Binding was not inuenced by
multivalency, as shown by the relative potency of binding per
carbohydrate (r.p./nFuc < 2 in all cases), or by additional positive
charges in the peptide sequences (Het7G2,Het8G2). Neverthe-
less the tetravalent fucosides FD2 and FD2x were the tightest
LecB ligands in the series.
The range of binding aﬃnities was much broader in the case
of the galactose specic lectin LecA ranging from KD ¼ 37 mM
for the monovalent galactopeptide GalBG0 down to KD¼ 2.5 nM
for the tetravalent galactoside GalAG2 (Table 3). Binding was
rst inuenced by the nature of the glycosidic group. All
compounds carrying an aromatic aglycone (the reference
nitrophenyl-b-galactoside NPG and all GalA containing prod-
ucts) showed a 10–20 fold stronger binding than their GalB
analogs containing an aliphatic chain as aglycone, reecting the
previously documented favourable CH–p interaction between
the aromatic group and the 3-CH of residue His50 on the lec-
tin.32 As for LecB, the monovalent Het1G1-Cys and Het2G1-Cys
bound poorly and gave high n values which might be caused by
disulde bond formation and/or aggregation. Furthermore
LecA behaved as a typical lectin by showing enhanced binding
to multivalent ligands.40 For the aromatic galactosides, the
relative potency of binding per galactoside reached r.p./nGal ¼Table 2 Thermodynamic parameters and binding data for the interactio
Ligand nFuc n
b DH [kcal mol1] TD
FucOCH3 1 0.77  0.03 9.87  0.24 1.
FD0 1 0.80  0.01 9.93  0.33 0.
Het1G1-Cys 1 1.64  0.00 4.82  0.01 2.
Het2G1-Cys 1 2.14  0.03 3.53  0.024 4.
FD1 2 0.28  0.01 23.87  1.21 14.
FD1-Cys 2 0.65  0.01 10.71  0.01 1.
Het1G2 2 0.40  0.05 15.9  0.05 6.
Het2G2 2 0.66  0.05 15.2  0.02 6.
Het3G2 2 0.31  0.01 25.15  2.75 15.
Het4G2 2 0.21  0.01 35.25  0.02 25.
Het7G2 2 0.30  0.02 25.1  0.02 16.
Het8G2 2 0.28  0.02 24.8  0.06 15.
FD2 4 0.16  0.01 40.9  1.25 30.
FD2x 4 0.59  0.02 9.72  0.9 0.
a Thermodynamic parameters and dissociation constants KD are reported
NaCl, 100 mM CaCl2, pH ¼ 7.5. Isothermal Titration Calorimetry (ITC) d
indicated in brackets: Me-a-fucose (0.44 mM/0.0558 mM), FD0 (0.5 mM/0
0.95 mM), FD1 (0.25 mM/0.0496 mM), FD1-Cys (0.0497 mM/0.5 mM), He
mM/0.042 mM), Het4G2 (0.24 mM/0.042 mM), Het7G2 (0.24 mM/0.042
(0.052 mM/0.5 mM). b n denes the stoichiometry of the binding. c R
number of copies of fucosides in the glycopeptide dendrimers. See ESI Fi
This journal is © The Royal Society of Chemistry 201620 in divalent galactosides GalAG1, Het1G2 and Het2G2, and
r.p./nGal ¼ 300 in tetravalent galactoside GalAG2 showing the
strongest binding. However GalAG2x only reached r.p./nGal ¼
32, showing that the ClAc ligated peptide dendrimer backbone
was less optimal for LecA binding compared to the original G2
peptide dendrimer. In the weaker binding aliphatic thio-
galactosides of the GalB series divalent dendrimers had
comparable relative potencies in the range 18 < r.p./nGal < 75,
including the more cationic heteroglycoclusters Het7G2 and
Het8G2. The tetravalent dendrimer GalBG2 reached a relative
potency of r.p./nGal ¼ 230 corresponding to KD ¼ 40 nM of
comparable value to aromatic galactosides.
Overall the ITC data showed that G2 heteroglycoclusters
achieved a relatively potent binding of both LecB and LecA at
levels comparable to those of G1 glycopeptide dendrimers
carrying only one type of carbohydrate. Binding aﬃnities
remained 2–10 fold weaker than that of the purely fucose or
purely galactose containing dendrimers FD2, FD2x, GalAG2,
GalAG2x and GalBG2, highlighting that the higher binding
aﬃnities of these G2 dendrimers required the tetravalent
display of four carbohydrates of the same type.Crystal structure of peptide dendrimer (Het1G1-Cys)2 as LecB
complex
A crystallography screen was undertaken to gain a structural
insight into the glycopeptide dendrimer lectin interaction. G2
heteroglycoclusters Het1G2 and Het2G2 and the parent G1
dendrimers Het1G1-Cys and Het2G1-Cys were tested as
complexes with either LecB or LecA by direct co-crystallization
or by soaking preformed lectin crystals with ligand. A well dif-
fracting crystal was obtained for the Het2G1-Cys$LecB complex,
which provided a dataset at 2.13 A˚ resolution. In this structuren of the homo- and heteroglycopeptide dendrimers with LecBa
S [kcal mol1] DG [kcal mol1] KD [nM] r.p./nFuc
c
17  0.24 8.70  0.02 430  10 1.8
99  0.05 8.34  0.02 770  20 1
79  0.03 7.61  0.024 2630  110 0.30
11  0.02 7.63  0.09 2570  400 0.30
43  1.10 9.43  0.10 123  2 3.1
81  0.02 8.89  0.05 300  25 1.3
89  0.30 8.94  0.01 276  1.5 1.4
28  0.03 8.92  0.01 292  57 1.3
91  2.82 9.23  0.09 179  27 2.1
79  0.15 9.43  0.03 121  5 3.2
14  0.24 8.96  0.02 327  6 1.2
61  0.07 9.17  0.02 193  4 2.0
83  1.7 9.80  0.09 66  1 2.9
99  0.9 9.62  0.02 88  2 2.2
as an average of two independent runs from ITC in 20 mM Tris, 100 mM
ata are for LecB binding. Titration concentrations for Ligand/LecB are
.044 mM), Het1G1-Cys (0.0457 mM/0.5 mM), Het2G1-Cys (0.0497 mM/
t1G2 (0.42 mM/0.042 mM), Het2G2 (0.42 mM/0.042 mM), Het3G2 (0.15
mM), Het8G2 (0.24 mM/0.042 mM), FD2 (0.1 mM/0.028 mM), FD2x
elative potency per fucoside r.p./nFuc ¼ KD(FD0)/KD(ligand)/n, nFuc ¼
g. S107 for ITC plots.
Chem. Sci., 2016, 7, 166–182 | 169
Table 3 Thermodynamic parameters and binding data for the interaction of the homo- and heteroglycopeptide dendrimers with LecAa
Ligand nGal n
b DH [kcal mol1] TDS [kcal mol1] DG [kcal mol1] KD [nM] r.p./nGald
NPGc 1 0.91  0.03 10.6  0.45 4.0 6.5 16 000  500 0.2
GalAG0 1 0.65  0.02 17.8  0.3 10.2 7.5 3000  50 1
Het1G1-Cys 1 1.17  0.04 7.83  0.26 0.85 7.0 7800  1200 0.4
Het2G1-Cys 1 1.37  0.09 7.36  0.093 0.35 7.0 7340  300 0.4
GalAG1 2 0.30  0.003 29  0.5 19.3 9.7 83  12 18
GalAG1-Cys 2 0.66  0.06 14.2  0.05 4.9 9.3 164  0.2 9
Het1G2 2 0.44  0.01 23.0  0.14 13.3 9.7 75  17 20
Het2G2 2 0.36  0.03 25.0  0.15 15.2 9.7 75  18 20
GalAG2 4 0.14  0.01 68.6  1.10 57 11.7 2.5  0.1 300
GalAG2x 4 0.21  0.02 32.4  0.47 22 10.4 23  0.3 32
GalBG0 1 0.71  0.01 14  0.04 7.8 6.0 37 000  800 1
GalBG1 2 0.37  0.02 20  0.1 12 8.2 1060  160 18
GalBG1-Cys 2 0.53  0.06 13.9  0.82 5.4 8.5 600  1 31
Het3G2 2 0.25  0.02 30.3  0.40 21 9.0 255  14 73
Het4G2 2 0.15  0.00 42.0  0.21 36 9.4 120  2 153
Het7G2 2 0.25  0.02 28.4  0.69 20 8.8 340  70 55
Het8G2 2 0.25  0.00 25.5  0.25 16.4 9.0 250  16 75
GalBG2 4 0.18  0.02 43  1 33 10.1 40  1 230
a Thermodynamic parameters and dissociation constants KD are reported as an average of two independent runs from ITC in 20 mM Tris, 100 mM
NaCl, 100 mM CaCl2, pH ¼ 7.5. Isothermal Titration Calorimetry (ITC) data are for LecA binding. Titration concentrations for Ligand/LecA are
indicated in brackets: NPG (3.0 mM/0.3 mM), GalAG0 (0.5 mM/0.0516 mM), Het1G1-Cys (1.2 mM/0.051 mM), Het2G1-Cys (0.57 mM/0.05 mM),
GalAG1 (0.25 mM/0.0486 mM), GalAG1-Cys (0.255 mM/0.05 mM), Het1G2 (0.25 mM/0.05 mM), Het2G2 (0.25 mM/0.05 mM), GalAG2 (0.03 mM/
0.018 mM), GalAG2x (0.0909 mM/0.0166 mM), GalBG0 (1.0 mM/0.091 mM), GalBG1 (0.25 mM/0.049 mM), GalBG1-Cys (0.4 mM/0.0526 mM),
Het3G2 (0.5 mM/0.1 mM), Het4G2 (0.1 mM/0.05 mM), Het7G2 (0.175 mM/0.05 mM), Het8G2 (0.175 mM/0.05 mM), GalBG2 (0.03 mM/0.08 mM).
b n dened the stoichiometry of the binding. c NPG is 4-nitrophenyl-b-D-galactopyranoside (reference used in the ITC measurements with LecA),
(3 mM/0.3 mM, Ligand/LecA). d Relative potency per galactoside. r.p./nGal ¼ KD(GalAG0 or GalBG0)/KD(ligand)/nGal. nGal ¼ number of copies of
galactosides in the glycopeptide dendrimer. See ESI Fig. S108 for ITC plots.
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View Article Onlineeach of the four carbohydrate binding sites on each LecB
tetramer is occupied by a fucose ligand. Two binding sites are
occupied by fucosyl groups attached to a fully visible Het2G1-
Cys ligand, whereby this ligand is oxidatively dimerized to
a disulde bridged (Het2G1-Cys)2 peptide dendrimer (Fig. 1A,
grey stick model and electron density). The other two LecB
binding sites are occupied by fucosyl groups where only the
terminal fucosylated tripeptide dendrimer arm is visible
(Fig. 1A, cyan stick model). This tripeptide adopts a stretched
conformation very similar to that of the fully resolved ligand,
and distinct from the more folded conformation previously
observed in a LecB complex with the fucosylated tripeptide FD0
(Fig. 1A: red stick model),19 consistent with attachment to the
dendrimer.Het2G1-Cys is possibly disordered or not oxidatively
dimerized and exible and therefore not visible at this crystal
position. All fucosyl groups adopt the typical position seen in
other fucose$LecB complexes, with binding interactions
between the C2(OH), C3(OH) and C4(OH) group of fucose and
the pair of Ca2+ ions and Asp99 on LecB. A tight (2.3 A˚) hydrogen
bond between the backbone amide of Asn70 and the phenyl-
alanyl–cysteine amide bond in the fully resolved ligand repre-
sents the only visible additional protein dendrimer contact.
The electron density of (Het2G1-Cys)2 observed at the fully
resolved crystal position is remarkable since it features the rst
example of a complete crystal structure of a G2 peptide den-
drimer. A closer analysis shows that this dendrimer bridges
binding sites on two diﬀerent LecB tetramers. Furthermore,
each (Het2G1-Cys)2 interacts with two further symmetrically170 | Chem. Sci., 2016, 7, 166–182positioned dendrimers via antiparallel b-sheets involving the C-
terminal tetrapeptides Leu-Lys-Phe-Cys (Fig. 1B). The arrange-
ment is repeated around the C3 symmetry axis such that three
dendrimers form a C3-symmetrical [(Het2G1-Cys)2]3 supramo-
lecular macrocycle with three fucosyl groups pointing above the
ring and three fucosyl groups below the ring and connecting six
diﬀerent LecB tetramers (Fig. 1C–F). The six galactosyl groups
are located within the supramolecular macrocycle and are
somewhat hidden from solution. Although this supramolecular
macrocycle is probably specic of the crystal lattice, one can
imagine that similar intermolecular b-sheet interactions might
occur in solution and cause sterical hindrance around single
carbohydrate groups, which could explain the unusually high
stoichiometry of binding observed in ITC for some of the den-
drimers. The absence of chelate binding mode with any of the
LecB tetramers in the present structure might be a general
feature of dendrimer LecB interactions, as suggested by the
absence of signicant multivalency eﬀect with all glycopeptide
dendrimers including the tightest binder FD2.Biolm inhibition by glycodendrimers and antimicrobial
compounds
Biolm inhibition activities were investigated next. In view of
a possible direct antimicrobial eﬀect of Het5G2–Het8G2 incor-
porating additional cationic residues in their sequences,
control non-glycosylated dendrimers were prepared to test the
eﬀect of the peptide backbone alone. These were the N-This journal is © The Royal Society of Chemistry 2016
Fig. 1 Crystal structure of dendrimer$LecB complex (PDB 5D2A, see also ESI† for crystal data table). A. Overlay view of a single LecB binding site
bound with (i) grey model and electron density: fully resolved (Het2G1-Cys)2 dendrimer; (ii) cyan model: terminal tripeptide at the partially
resolved crystal position; (iii) red model: tripeptide FD0, from ref. 19 in each case the peptide backbone is fully visible, but several side chains are
disordered and not visible, which is typical for peptides and loop residues in proteins B. Detail of the b-sheet interaction connecting two diﬀerent
(Het2G1-Cys)2 dimers. Dashed lines indicate H-bonded atoms that are 2.7 A˚ apart. C–F. Side and top view of the supramolecular macrocycle
[(Het2G1-Cys)2]3 binding to six LecB tetramers. Each of the three dendrimers and the two LecB tetramers to which it is bound have the same
color: orange, red, or grey.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 166–182 | 171
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View Article Onlineterminally acetylated peptide dendrimer AcG2 and its ClAc
ligation analog AcG2x, as well as the more cationic sequence
AcG2xK and peptide dendrimer NG2 with four free N-termini,
each carrying four additional positive charges (Table 4). Two
recently reported polycationic antimicrobial peptide den-
drimers with strong activity against P. aeruginosa presumably by
a membrane disrupting eﬀect, G3KL and G3LK,36 were also
included in the study, as well as the reference antibiotics poly-
myxin B and tobramycin (Table 5).Table 4 Non-glycosylated dendrimersa
Compound Sequence MS calc./obs.b Yieldc (mg/%)
AcG2 (Ac-KPL)4(KFKI)2KHI 2949.92/2949.92 26/7
AcG1-Cys (Ac-KPL)2KFC 1156.69/1156.69 38/19
AcG1K-Cys (Ac-KKL)2KFC 1217.78/1218.78 76/50
AcG2x (Ac-KPL)4(KFCxKI)2KHI 3269.99/3270.99 4.8/50
AcG2xK (Ac-KKL)4(KFCxKI)2KHI 3392.43/3393.18 5.9/60
NG2 (KPL)4(KFKI)2KHI 2781.88/2781.88 8/44
G3KLd (KL)(KKL)4(KKL)2KKL 4534.19/4535.10 52.2/8
G3LKd (LK)(KLK)4(KLK)2KLK 4534.19/4534.84 7.8/1
a One letter code for L-amino acids. Lys ¼ branching lysine residue, x ¼
–S–CH2–CO–. Ac ¼ acetyl. C-termini are carboxamides CONH2. b MS
calc. for [M + H]+/MS obs. determined by ESI+. c Yields are reported
for the RP-HPLC puried products. d From ref. 36.
Table 5 Inhibition of Pseudomonas aeruginosa bioﬁlms
Compound MBICa[mM] MBCb[mM]
FD2 20 >30
GalAG2 20 >30
GalBG2 20 nd
FD2x 45 >45
GalAG2x 30 30
GalBG2x 30 >45
Het1G2 30 >45
Het2G2 30 >45
Het3G2 >45 >45
Het4G2 >45 >45
(Het2G1-Cys)2 >45 nd
Het5G2 20 20
Het6G2 20 20
Het7G2 13 13
Het8G2 20 20
AcG2 30 30
AcG2x 30 30
AcG2xK 13 13
NG2 2.5 2.5
G3KL 4 6
G3LK 6 9
Polymyxin B 6 6
Tobramycin 0.5 0.5
a MBIC is minimal biolm inhibitory concentration. b MBC ¼minimal ba
by CFU counts in the biolm supernatant and growth test in full medium.
of already established biolms. d MIC ¼ minimal inhibitory concentratio
medium. n.i. ¼ no inhibition in a growth assay using 50 mM compound,
also ESI Fig. S110–S114 (biolm inhibition), S116 (biolm dispersal), S1
growth curves).
172 | Chem. Sci., 2016, 7, 166–182Biolm inhibition wasmeasured by determining the amount
of biolm formed aer 24 h of growth with or without
compound at diﬀerent concentrations. The biolm was quan-
tied using the WST-8 assay indicating the amount of viable
cells as previously described.31 To distinguish between biolm
inhibition and a direct bactericidal eﬀect, the number of viable
cells in the supernatant was also determined by CFU (colony
forming unit) counts and by a growth test in an inoculated full
medium (OD600 measurement aer 7–8 h growth). In a third
assay, the ability of the compounds to disperse already estab-
lished biolms was tested by preincubating the bacteria under
biolm forming conditions for 24 h, followed by addition of the
test compound at a xed concentration, incubation for an
additional 24 h, and quantication of the remaining biolm as
above. Finally, biolm inhibitory compounds were also tested
for their direct bactericidal activity under full medium either by
determination of the minimal inhibitory concentration (MIC)
by standard serial dilution series, or with a measurement of
their eﬀect on bacterial growth in full medium.
All dendrimers except the GalB containing hetero-
glycoclusters Het3G2 and Het4G2 showed substantial biolm
inhibition activity at a level comparable to the reference biolm
inhibitor FD2 (MBIC ¼ 20 mM). Most of these dendrimers were
also able to disperse already established biolms, the most
potent compound still being the parent fucosylated dendrimer
FD2. Except for GalAG2x all dendrimers derived from the parentDispersalc MICd
100% dispersal n.i.e
50% dispersal n.i.
60% dispersal nd
35% dispersal nd
100% dispersal nd
Increase nd
30% dispersal nd
35% dispersal nd
85% dispersal nd
No dispersal nd
No dispersal nd
100% dispersal >64 mM
100% dispersal >64 mM
100% dispersal >64 mM
100% dispersal >64 mM
100% dispersal n.i.
Increase nd
100% dispersal >64 mM
100% dispersal @ 22 mM >64 mM
95% dispersal @ 10 mM 0.44 mM
95% dispersal @ 10 mM 2 mM
70% dispersal @ 10 mM 2 mg mL1f
100% dispersal @ 4 mM 1 mg mL1g
ctericidal concentration under biolm forming conditions, determined
c Eﬀect of the compounds at 50 mM or concentration stated on dispersal
n in a standard 2-fold dilution assay for antibacterial activity in full LB
nd ¼ not determined. e From ref. 19. f From ref. 36. g From ref. 41. See
17–119 (MIC data), Table S1 (cell viability data) and Table S2 (control
This journal is © The Royal Society of Chemistry 2016
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View Article Onlinepeptide sequence of FD2 were not bactericidal at their MBIC
concentration, showing that their biolm inhibition activity was
not caused by a simple bactericidal eﬀect. The related disulde-
bridged heterodimer (Het2G1-Cys)2 described above as a LecB
complex was not active as a biolm inhibitor.Scheme 2 Synthesis of LeaC6G2 and FucC6G2. Conditions: (a) N-
Iodosuccinimide, AgOTf, CH2Cl2, 0 C, 30 min (quant.); (b) H2,
Pd(OH)2, THF, AcOH, 17 h, 25 C; (c) pyridine/Ac2O, cat. DMAP/NMM,
CH2Cl2, 25 C, 4 h (55% over 2 steps); (d) TBAF, AcOH, 25 C, 17 h
(60%); (e) Cl3CCN, DBU, CH2Cl2, 0 C, 40 min (80%); (f) AcS(CH2)6OH,
TMSOTf, CH2Cl2, 0 C, 20 min (64%); (g) K2CO3, MeOH, 25 C, 1 h
(75%); (h)ClAcD2, KI, DIPEA, H2O/CH3CN, 25 C, 17 h, then prep. HPLC
(63%); (i) step f (84%); (j) step g (75%); (k) step h (31%). See ESI† for
synthesis details.
Table 6 Synthesis of FD2 analogs by ClAc ligationa
Compound Sequence
ClAcD2 (ClCH2CO–KPL)4(KKI)2KHI
FucC6G2 (Fuc–O–(CH2)6–S–CH2CO–KPL)4(KKI)2KHI
LeaC6G2 (Le
a–O–(CH2)6–S–CH2CO–KPL)4(KKI)2KHI
a One letter code for amino acids. Branching Lys in italics. The peptid
determined by ESI+. Yield is reported for the RP-HPLC puried product a
This journal is © The Royal Society of Chemistry 2016Polycationic heteroglycoclusters Het5G2–Het8G2 also
showed good activities, however these compounds were toxic at
their biolm inhibitory concentration as evidenced by
a comparable minimal bactericidal concentration (MBC) value
determined by CFU counts of the supernatant and growth test.
The control, non-glycosylated dendrimers AcG2, AcG2x and
their analogs AcG2xK and NG2 with an additional four positive
charges were also bactericidal at their biolm inhibition
concentration. A similar bactericidal antibiolm eﬀect was
detected with the polycationic antimicrobial peptide den-
drimers G3KL and G3LK as well as with antibiotics polymyxin B
and tobramycin. All of these bactericidal compounds were
furthermore able to disperse already established biolms,
although the eﬀect was not as complete as observed with gly-
codendrimer FD2, and at least 10-fold higher concentrations
were necessary compared to their MIC values determined in full
medium, where bacteria grow in suspension (planktonic state).
The biolm inhibition study highlighted the remarkable non-
toxic biolm inhibition and dispersal eﬀect of glycopeptide
dendrimers such as FD2 in contrast to the direct bactericidal
eﬀect of polycationic dendrimers and antibiotics.Multivalent Lewisa dendrimers
The above study showed that tetrafucosylated dendrimer FD2
remained the most potent non-toxic biolm inhibitor among
the diﬀerent glycopeptide dendrimers tested. A second varia-
tion study was therefore undertaken focusing on variation of
the fucosyl group of this dendrimer. Analogs of FD2 were
prepared by the ClAc ligation approach using carbohydrate
building blocks appended with a nucleophilic hexylthiol tether.
The ligation was performed onto a tetrachloroacetylated den-
drimer ClAcD2 derived from FD2 in which the phenylalanine
residue in the G1 branch had been removed to compensate for
the introduction of the alkylthiol tether in terms of hydropho-
bicity and overall arm length of the dendrimers. This approach
did not require excess of non-peptidic reagents and therefore
allowed to consider more complex carbohydrates. We focused
on preparing a tetravalent peptide dendrimer version of the
Lewisa trisaccharide, which is the tightest monovalent binder
known for LecB and its probable natural ligand.37
To obtain the desired Lea trisaccharide, L-fucosyl donor 1
and the selectively protected disaccharide 2 with a single free
hydroxyl group at position C(4) of its glucosamine component
were synthesized by published procedures,42,43 and coupled by
glycosylation to give a protected Lewisa trisaccharide. RemovalMS calc./obs.a Yield (mg/%)
2791.64/2791.64 43/17b
3768.27/3768.27 2.5/31c
5228.80/5228.80 8/63c
e C-terminus is carboxamide CONH2.
aMS calc. for [M + H]+/MS obs.
er bSPPS or cClAc ligation.
Chem. Sci., 2016, 7, 166–182 | 173
Table 7 Thermodynamic parameters and binding data for the interaction of FucC6 and Lea glycopeptide dendrimers with LecBa
Ligand nFuc n
b DH [kcal mol1] TDS [kcal mol1] DG [kcal mol1] KD[nM] r.p./nsugar
FucOCH3 1 0.77  0.03 9.87  0.24 1.17  0.24 8.70  0.02 430  10 1
Lea 1 1.08  0.01 8.35  0.02 0.74  0.002 9.10  0.02 213  2.0 2
FucC6G2 4 0.22  0.01 14.7  0.38 5.20  0.28 9.44  0.09 121  20 0.9c
LeaC6G2 4 0.12  0.01 58.5  1.17 48.5  1.65 10.1  0.06 39  0.8 2.8c
a Thermodynamic parameters and dissociation constants KD are reported as an average of two independent runs from ITC in 20 mM Tris, 100 mM
NaCl, 100 mM CaCl2, pH ¼ 7.5. Isothermal Titration Calorimetry (ITC) data are for LecB binding. Titration concentrations for Ligand/LecB are
indicated in brackets: Lea (0.324 mM/0.0327), FucC6G2 (0.3 mM/0.08 mM), Le
aC6G2 (0.07 mM/0.042 mM).
b n dened the stoichiometry of the
binding. c Relative potency per fucoside. r.p./nFuc ¼ KD(FucOCH3)/KD(ligand)/nFuc. See ESI Fig. S107 for ITC plots.
Table 8 Activity of FucC6 and Lea glycopeptide dendrimers against Pseudomonas aeruginosa bioﬁlms
Ligand MBICa [mM] MBCb [mM] Dispersal MICc
FD2 20 >30 100% dispersal at 50 mM n.i.d
FucC6G2 9 >20 100% dispersal at 30 mM >64 mM
LeaxG2 30 nd 88% dispersal at 50 mM nd
a MBIC is minimal biolm inhibitory concentration. b MBC ¼minimal bactericidal concentration under biolm forming conditions, determined
by CFU counts in the biolm supernatant. c MIC ¼minimal inhibitory concentration in a standard 2-fold dilution assay for antibacterial activity in
full LB medium. n.i. ¼ no inhibition in a growth assay using 50 mM compound, nd ¼ not determined. d From ref. 19. See also ESI Fig. S115/S116
(biolm data), S120 (MIC data), and Table S1 (cell viability data).
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View Article Onlineof benzyl ethers and azide reduction by catalytic hydrogenation,
acetylation, desilylation of the anomeric hydroxyl group,
formation of the trichloroacetimidate and Schmidt glyco-
sydation of 6-hydroxyhexyl-thioacetate then gave the protected
thiol tethered Lewisa trisaccharide 3. Finally, deacetylation and
ligation with dendrimer ClAcD2 gave the desired G2 dendrimer
LeaC6G2. The tethered protected b-fucoside 5 was similarly ob-
tained from intermediate 4.43 Deacetylation and ligation with
ClAcD2 as above gave G2 dendrimer FucC6G2 (Scheme 2, Table
6).
The tetravalent dendrimers LeaC6G2 and FucC6G2 showed
the expected binding aﬃnities to LecB as measured by ITC, with
simply additive but nomultivalency eﬀect on binding compared
to their parent monovalent ligand. Nevertheless the slightly
tighter LecB binding of Lewisa compared to simple fucosyl
groups and a slightly more than additive eﬀect on LecB binding
in the dendrimer resulted in KD ¼ 39 nM for LeaC6G2, such that
this rst multivalent version of the Lewisa antigen represents
one of the tightest LecB ligands reported thus far (Table 7).
Both compounds showed biolm inhibition and dispersal
activities in the same range as the parent FD2, with a slightly
stronger biolm inhibition in the case of FucC6G2 with MBIC ¼
9 mM. In both cases the compounds were not bactericidal,
conrming the absence of toxicity for this type of glycosylated
peptide dendrimer biolm inhibitors. Considering its relatively
straightforward and eﬃcient synthesis, FucC6G2 stood out as
an improved version of biolm inhibitor FD2 (Table 8).Synergistic eﬀects between glycopeptide dendrimer biolm
inhibitors and tobramycin
The MBIC value of 9 mM reached with FucC6G2, although the
best value among non-toxic glycopeptide dendrimers, still174 | Chem. Sci., 2016, 7, 166–182represented an activity of only 34 mg mL1 due to the high
molecular weight of the compound (MW ¼ 3.7 kDa), implying
that further improvement were necessary to reach a practically
useful compound. To search for further activity improvements,
possible synergistic eﬀects between our glycopeptide den-
drimers and antimicrobial compounds were investigated.
Synergistic eﬀects between diﬀerent antibiotics are well known,
and combination therapies with multiple antibiotics are
commonly used in the clinic.44–47
Here we focused on synergistic eﬀect with tobramycin,
a classical aminoglycoside antibiotic targeting the ribosome,
against which P. aeruginosa readily acquires resistance. Indeed
synergistic eﬀects have been previously reported between
tobramycin and iron chelators, which act as P. aeruginosa bio-
lm inhibitors in airway epithelial cystic brosis cells.48,49 A
survey with various glycopeptide dendrimers showed that co-
application of FD2 and tobramycin eﬀected a synergistic biolm
inhibition eﬀect, with both compounds acting at sub-inhibitory
concentration (Fig. 2A), allowing to use only 5 mM of FD2, which
is 4-fold lower than its MBIC value, and 0.1 mM tobramycin,
which is 5-fold lower than its MBIC value, thus achieving
a remarkable synergistic eﬀect (Table 9). A similar co-applica-
tion of subinhibitory concentrations of tobramycin with
FucC6G2 also acted as toxic biolm inhibitors, however without
decreasing the MBIC of FucC6G2 itself (Fig. 2E). In terms of
biolm dispersal application of subinhibitory concentrations of
tobramycin also lowered the dispersal concentration of FD2 by
4-fold (Fig. 2B) but not that of FucC6G2 (Fig. 2F). The eﬀects can
be interpreted in terms of triggering a non-toxic dispersal of the
biolm by the glycopeptide dendrimers, allowing facilitated
entry of the toxic tobramycin into the cells.This journal is © The Royal Society of Chemistry 2016
Fig. 2 Inhibition and dispersal of Pseudomonas aeruginosa strain PA01 bioﬁlms by synergy. (A) Bioﬁlm inhibition with FD2/Tobramycin. (B)
Bioﬁlm dispersal with FD2/Tobramycin. (C) Bioﬁlm inhibition with FD2/G3KL. (D) Bioﬁlm dispersal with FD2/G3KL. (E) Bioﬁlm inhibition with
FucC6G2/Tobramycin. (F) Bioﬁlm dispersal with FucC6G2/Tobramycin. For inhibition, bioﬁlms were grown onmicrotiter plates for 24 hours at 37
C in the presence of the indicated compounds, and viable bioﬁlms were stained with WST-8/PE. For dispersal, bioﬁlms were ﬁrst grown on
microtiter plates for 24 hours at 37 C in the absence of any compounds, planktonic bacteria were removed, and the bioﬁlms were incubated
with compounds for another 24 hours. Viable bioﬁlms were stained with WST-8/PES. See also Table 9.
Table 9 Bioﬁlm inhibition and dispersal by co-application of tobra-
mycin or G3KL with FD2
Compound Antimicrobial compound MBIC [mM] Dispersala [mM]
FD2 — 20 50
FD2 Tobramycin 0.1 mM 5 10
FucC6G2 — 9 30
FucC6G2 Tobramycin 0.1 mM 9 20
FD2 G3KL 1.2 mM 5 20
FD2 G3KL 0.1 mM 10 20
a
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View Article OnlineA similar synergistic eﬀect was obtained by combining FD2
with the antimicrobial peptide dendrimer G3KL lowering of the
MBIC value of each compound by 4 to 5-fold. Most strikingly,
even a 0.1 mM application of G3KL induced cytotoxic biolm
inhibition at only 10 mM FD2 (Fig. 2C), and dispersal at only 20
mM (Fig. 2D). As for tobramycin, the biolm disrupting eﬀect of
FD2 probably facilitates access of G3KL to the bacteria. Overall
these experiments suggest that the non-toxic biolm inhibitor
FD2 might be useful to increase the sensitivity of P. aeruginosa
to standard antibiotics.Concentration necessary to disperse 100% of the biolm, see also
legend of Fig. 2.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 166–182 | 175
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View Article OnlineConclusion
In summary an extensive search for improved analogs of our
previously reported glycopeptide dendrimer inhibitors of P.
aeruginosa biolms FD2 and GalAG2 was carried out exploiting
the multivalent chloroacetyl cysteine thioether (ClAc) ligation.
G2 heteroglycoclusters displaying a pair of fucosyl groups tar-
geting the fucose specic P. aeruginosa lectin LecB and a pair of
galactosyl groups targeting the galactose specic lectin LecA
achieved binding to both lectins at the level of G1 peptide
dendrimers. One of the heteroglycoclusters provided the rst
fully resolved crystal structure of a peptide dendrimer as a LecB
complex, revealing a supramolecular arrangement of three
dendrimers connected via b-sheets and cross-linking six
diﬀerent LecB tetramers without chelate binding, consistent
with the absence of multivalency eﬀects by multivalent ligands
of this lectin. Hetereoglycoclusters Het1G2–Het4G2 inhibited P.
aeruginosa biolms at levels comparable to the parent glyco-
dendrimers FD2 and GalAG2. Analogs Het5G2–Het8G2 with
additional positive charges showed stronger biolm inhibition
and dispersal, however the gain in activity reected a direct
bactericidal eﬀect of the dendrimers comparable to other pol-
ycationic dendrimers such as the antimicrobial peptide den-
drimer G3KL and the control, non-glycosylated dendrimer
backbone NG2. In a second approach G2 glycopeptide den-
drimers displaying four copies of the Lewisa antigen, which is
the natural LecB ligand, yielded slightly stronger LecB ligands
and biolm inhibitors. Finally a search for synergistic eﬀects
between non-toxic glycopeptide dendrimer biolm inhibitors
and classical antibiotics revealed that biolm inhibition and
dispersal could be achieved by co-application of dendrimer FD2
and the antibiotic tobramycin at sub-inhibitory concentrations
of both compounds. A similar synergistic eﬀect was observed by
combining FD2 with the antimicrobial peptide dendrimer
G3KL, allowing to inhibit biolm with both compound signi-
cantly below their MBIC value. The synergistic use of non-toxic
glycopeptide dendrimer biolm inhibitors to restore sensitivity
to antibiotics might oﬀer new opportunities to address antibi-
otic resistance in P. aeruginosa.
Materials and methods
Synthesis
Amino acids were used as the following derivatives: Fmoc-
His(Trt)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Ile-OH, Fmoc-
Pro-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Fmoc)-OH, Fmoc-
Cys(Trt)-OH, Fmoc-Ser(tBu)-OH. Chemicals were used as
supplied and solvents were of analytical grade. Analytical RP-
UHPLC was performed in Dionex ULTIMATE 3000 RS chroma-
tography system (ULTIMATE 3000 RS photo diode array
detector) using a Dionex Acclaim® RSLC 120 C18, 3.0  50 mm,
particle size 2.2 mm, 120 A˚ pore size, ow rate 1.2 mL min1
column. Eluent A contained water with 0.1% TFA; eluent D
contained acetonitrile and water (90 : 10) with 0.1% TFA.
Compounds were detected by UV absorption at 214 nm.
Preparative RP-HPLC was performed with a Waters PrepLC4000
chromatography system using a Dr Maish GmbH Reprospher176 | Chem. Sci., 2016, 7, 166–182Column (C18-DE, 5 mm, 100  30 mm, pore size 100 A˚, ow rate
of 40 mLmin1); compounds were detected by UV absorption at
214 nm using a Waters 486 Tunable Absorbance detector or
with Waters automatic PrepLC with the four following modules:
Waters2489 UV/Vis detector, Waters2545 pump, Waters Frac-
tion Collector III and Waters 2707 Autosampler. For the auto-
matic system, data recording and processing was performed
with Waters ChromScope version 1.40 from Waters Corpora-
tion. All RP-HPLC were using HPLC-grade acetonitrile andMilli-
Q deionized water. The elution solutions were: (A) MilliQ
deionized water containing 0.1% TFA; (B) MilliQ deinoized
water/acetonitrile (50 : 50, v/v); (D) MilliQ deionized water/
acetonitrile (10 : 90, v/v) containing 0.1% TFA. MS spectra were
provided by the Service of Mass Spectrometry of the Department
of Chemistry and Biochemistry, University of Bern. See ESI† for
images of analytical HPLC and MS spectra of all compounds.Solid-phase peptide synthesis
TentaGel S RAM resin (500 mg, loading: 0.22–0.26 mmol g1)
was loaded in a 10 mL polypropylene syringe tted with a poly-
propylene frit, a Teon stopcock, and a stopper. The resin was
swollen in DCM (6 mL, 20 min). Aer removal of the DCM, the
Fmoc-protecting group of the resin was removed using a solu-
tion of 20% piperidine in NMP. Stirring of the reaction mixture
was performed by attaching the closed syringes to a rotating
axis. The completion of the reaction and the removal of the
Fmoc protecting group were checked using the TNBS test (1
drop of 1% TNBS in DMF and 1 drop 10% DIPEA in DMF).
Orange or red beads indicated successful deprotection, color-
less beads indicated a complete coupling reaction. In case of
proline, the chloranil-test (1 drop of 2% chloranil in DMF and 1
drop 2% acetaldehyde in DMF) for secondary amines was used.
In this case, violet or dark green beads indicated successful
deprotection as colorless beads indicated complete coupling
reaction. Removal of the Fmoc protecting group was performed
by using a solution of 20% piperidine in NMP (6 mL, 20 min).
Aer ltration, the resin was washed with NMP (2  6 mL),
MeOH (2  6 mL) and DCM (2  6 mL).
Coupling of the Fmoc-protected amino acids was performed
using Fmoc-protected amino acids (3 eq.), PyBOP (3 eq.) and
DIPEA (6 eq.) in NMP (6mL). The reaction times for linear peptides
were 1 hour, for G1 dendrimers 1.5 hours and for G2 dendrimers 2
hours. The resin was then washed with NMP (2 6 mL), MeOH (2
 6 mL) and DCM (2  6 mL). Capping of free amine groups was
performed aer each amino acid coupling using a solution of
acetic anhydride : dichloromethane (1 : 1, v/v).
For allyl/alloc deprotection, the polypropylene syringe was
equipped with a septum and dried under high vacuum for one
hour. Then it was swollen in dry DCM for 10 min under argon.
Aer removal of the solvent, Pd(PPh3)4 (0.15 eq.) and PhSiH3 (15
eq.) were diluted in 4 mL of dry DCM and added to the resin
under argon. The reaction was stirred under argon bubbling for
20 min. The reagents were then removed by ltration and the
resin washed with dry DCM. The alloc deprotection procedure
was repeated for another 20 min. Finally, the resin was washedThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinewith sodium diethylcarbamate solution (0.02 M in DMF) and
then with DCM (8 mL, 2  10 min).
N-Chloroacetylation of the resin was performed with a solu-
tion of chloracetic acid anhydride (10 eq. per free N-terminus) in
NMP (5 mL) for 2  10 min. The resin was then washed with
NMP (2  6 mL), MeOH (2  6 mL) and DCM (2  6 mL).
Carbohydrate coupling was performed by using the pro-
tected peracetylated sugar derivative (4 eq. per N-terminus for
GalA and GalB, 5 eq. per N-terminus for c-fucoside), HATU (3 eq.
per arm) and DIPEA (5 eq. per arm) in NMP (6 mL). The resin
was stirred overnight. The resin was washed with NMP (2  6
mL), MeOH (2  6 mL) and DCM (2  6 mL). The deprotection
of the carbohydrates was performed by basic methanolysis with
a solution of MeOH/25% NH3/H2O (8 : 1 : 1, v/v/v). The resin
was washed with NMP (2  6 mL), MeOH (2  6 mL) and DCM
(2  6 mL) and dried.
Acetylation of the N-termini was performed by using acetic
anhydride : dichloromethane (1 : 1, v/v) for 20 min. The resin
was washed with NMP (2  6 mL), MeOH (2  6 mL) and DCM
(2  6 mL).
TFA cleavage was performed by adding a solution of TFA/TIS/
H2O (95 : 2.5 : 2.5, v/v/v) to the resin for 2.5–3 hours. Peptide
dendrimers containing Cys residues were cleaved with TFA/TIS/
H2O/1,2-ethanedithiol (92.5 : 2.5 : 2.5 : 2.5, v/v/v/v). The peptide
dendrimers were then precipitated with ice-cold TBME and
removed from TBME by centrifugation. The crude product was
dried at high-vacuum to remove residual TFA and TBME.
For purication, the crude was dissolved in MilliQ deionized
water containing 0.1% TFA or in a mixture of MilliQ deionized
water and acetonitrile containing 0.1% TFA. The purication
was performed by HPLC. The obtained products were analysed
by analytical RP-UHPLC, ESI-MS and amino acid analysis.
FD1-Cys. (cFuc-KPL)2KFC was obtained from 500 mg resin
(loading 0.25 mmol g1) as a foamy white solid aer preparative
RP-HPLC (33.5 mg, 23 mmol, 18%). Analytical RP-UHPLC: tR ¼
1.398 min (A/D 100/0 to 0/100 in 2.2 min, ow rate 1.2 mL
min1, l¼ 214 nm). MS (ESI+) calc. for C68H113N13O19S [M + H]+:
1448.81, found: 1447.80.
GalAG1-Cys. (GalA-KPL)2KFC was obtained from 500 mg
resin (loading 0.25 mmol g1) as a foamy white solid aer
preparative RP-HPLC (79 mg, 48 mmol, 39%). Analytical RP-
UHPLC: tR ¼ 1.419 min (A/D 100/0 to 0/100 in 2.2 min, ow rate
1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for C78H117N13O23S
[M + H]+: 1636.82, found: 1637.82 (z ¼ 1), 819.41 (z ¼ 2).
GalBG1-Cys. (GalB-KPL)2KFC was obtained from 500 mg
resin (loading 0.25 mmol g1) as a foamy white solid aer
preparative RP-HPLC (29.5 mg, 18 mmol, 15%). Analytical RP-
UHPLC: tR ¼ 1.420 min (A/D 100/0 to 0/100 in 2.2 min, ow rate
1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for C70H117N13O21S3
[M + H]+: 1572.77, found: 1573.78 (z ¼ 1), 786.89 (z ¼ 2).
Het1G1-Cys. cFuc-KPLK(GalA-KPL)FC was obtained from 500
mg resin (loading 0.25 mmol g1) as a foamy white solid aer
preparative RP-HPLC (63 mg, 41 mmol, 33%). Analytical RP-
UHPLC: tR ¼ 1.454 min (A/D 100/0 to 0/100 in 2.2 min, ow rate
1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for C73H115N13O21S
[M + H]+: 1542.82, found: 1543.81 (z ¼ 1), 771.91 (z ¼ 2).This journal is © The Royal Society of Chemistry 2016Het2G1-Cys. GalA-KPLK(cFuc-KPL)FC was obtained from 500
mg resin (loading 0.25 mmol g1) as a foamy white solid aer
preparative RP-HPLC (50 mg, 32 mmol, 26%). Analytical RP-
UHPLC: tR ¼ 1.457 min (A/D 100/0 to 0/100 in 2.2 min, ow rate
1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for C73H115N13O21S
[M + H]+: 1542.82, found: 1543.81 (z ¼ 1), 771.91 (z ¼ 2).
Het3G1-Cys. cFuc-KPLK(GalB-KPL)FC was obtained from 500
mg resin (loading 0.25 mmol g1) as a foamy white solid aer
preparative RP-HPLC (52 mg, 34 mmol, 28% yield). Analytical
RP-UHPLC: tR ¼ 1.462 min (A/D 100/0 to 0/100 in 2.2 min, ow
rate 1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for
C69H115N13O20S2 [M + H]
+: 1510.79, found: 1510.79 (z ¼ 1),
755.90 (z ¼ 2).
Het4G1-Cys. GalB-KPLK(cFuc-KPL)FC was obtained from 500
mg resin (loading 0.25 mmol g1) as a foamy white solid aer
preparative RP-HPLC (50 mg, 33 mmol, 26%). Analytical RP-
UHPLC: tR ¼ 1.454 min (A/D 100/0 to 0/100 in 2.2 min, ow rate
1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for C69H115N13O20S2
[M + H]+: 1510.79, found: 1510.78 (z ¼ 1), 755.90 (z ¼ 2).
Het5G1-Cys. cFuc-KKLK(GalA-KKL)FC was obtained from
500 mg resin (loading 0.25 mmol g1) as a foamy white solid
aer preparative RP-HPLC (29.4 mg, 18 mmol, 15%). Analytical
RP-UHPLC: tR ¼ 2.464 min (A/D 100/0 to 0/100 in 7.5 min, ow
rate 1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for
C75H125N15O21S [M +H]
+: 1604.90, found: 1604.90 (z¼ 1), 802.95
(z ¼ 2).
Het6G1-Cys. GalA-KKLK(cFuc-KKL)FC was obtained from
500 mg resin (loading 0.25 mmol g1) as a foamy white solid
aer preparative RP-HPLC (32.5 mg, 20 mmol, 16%). Analytical
RP-UHPLC: tR ¼ 2.483 min (A/D 100/0 to 0/100 in 7.5 min, ow
rate 1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for
C75H125N15O21S [M +H]
+: 1604.90, found: 1604.90 (z¼ 1), 802.95
(z ¼ 2), 535.64 (z ¼ 3).
Het7G1-Cys. cFuc-KKLK(GalB-KKL)FC was obtained from
500 mg resin (loading 0.25 mmol g1) as a foamy white solid
aer preparative RP-HPLC (66 mg, 42 mmol, 34%). Analytical
RP-UHPLC: tR ¼ 2.390 min (A/D 100/0 to 0/100 in 7.5 min, ow
rate 1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for
C71H125N15O20S2 [M + H]
+: 1572.88, found: 1573.88 (z ¼ 1),
787.44 (z ¼ 2), 525.30 (z ¼ 3).
Het8G1-Cys. GalB-KKLK(cFuc-KKL)FC was obtained from
500 mg resin (loading 0.25 mmol g1) as a foamy white solid
aer preparative RP-HPLC (52 mg, 33 mmol, 26%). Analytical
RP-UHPLC: tR ¼ 1.369 min (A/D 100/0 to 0/100 in 2.2 min, ow
rate 1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for
C71H125N15O20S2 [M + H]
+: 1572.88, found: 1572.87 (z ¼ 1),
766.04 (z ¼ 2), 524.90 (z ¼ 3).
ClAcG1. (ClAc-KI)2(KHI) was obtained from 500 mg resin
(loading 0.25 mmol g1) as a foamy white solid aer preparative
RP-HPLC (89 mg, 86 mmol, 70%). Analytical RP-UHPLC: tR ¼
1.443 min (A/D 100/0 to 0/100 in 2.2 min, ow rate 1.2 mL
min1, l ¼ 214 nm). MS (ESI+) calc. for C46H81Cl2N13O9 [M +
H]+: 1030.58, found: 1029.57.
AcG1-Cys. (Ac-KPL)2KFC was obtained from 500 mg resin
(loading 0.25 mmol g1) as a foamy white solid aer preparative
RP-HPLC (37.8 mg, 33 mmol, 19%). Analytical RP-UHPLC: tR ¼Chem. Sci., 2016, 7, 166–182 | 177
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View Article Online1.497 min (A/D 100/0 to 0/100 in 2.2 min, ow rate 1.2 mL
min1, l ¼ 214 nm). MS (ESI+) calc. for C56H93N13O11S [M + H]+:
1156.69, found: 1156.69 (z ¼ 1), 578.85 (z ¼ 2).
AcG1K-Cys. (Ac-KKL)2KFC was obtained from 500 mg resin
(loading 0.25 mmol g1) as a foamy white solid aer preparative
RP-HPLC (75.9 mg, 62 mmol, 50%). Analytical RP-UHPLC: tR ¼
1.359 min (A/D 100/0 to 0/100 in 2.2 min, ow rate 1.2 mL
min1, l¼ 214 nm). MS (ESI+) calc. for C59H104N14O11S [M + H]+:
1217.78, found: 1218.78 (z ¼ 1), 609.89 (z ¼ 2).
NG2. (KPL)4(KKI)2KHI was obtained from 500 mg resin
(loading 0.25 mmol g1) as a foamy white solid aer preparative
RP-HPLC (8 mg, 2.88 mmol, 44%). Analytical RP-UHPLC: tR ¼
1.390 min (A/D 100/0 to 0/100 in 2.2 min, ow rate 1.2 mL
min1, l ¼ 214 nm). MS (ESI+) calc. C140H241N35O23 [M + H]+:
2781.88, found: 2781.88 (z ¼ 1), 1391.95 (z ¼ 2), 928.30 (z ¼ 3),
696.48 (z ¼ 4), 557.38 (z ¼ 5).
ClAcD2. (ClAc-KPL)4(KKI)2KHI was obtained from 500 mg
resin (loading 0.25 mmol g1) as a foamy white solid aer
preparative RP-HPLC (42.5 mg, 15 mmol, 17%). Analytical RP-
UHPLC: tR ¼ 1.545 min (A/D 100/0 to 0/100 in 2.2 min, ow rate
1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. MS (ESI+) calc. for
C130H227Cl4N33O25 [M + H]
+: 2791.64, found: 2791.64.Chloroacetyl cysteine (ClAc) ligation
A solution of core dendrimer (sequence containing chloroacetyl
endgroups, around 3 mg, 1 eq.) and KI (20 eq.) in MeCN/H2O
(1 : 1, v/v) (300 mL) was prepared in a 2 mL glass vial. The
mixture was ushed with Ar during 10 min. In another 2 mL
glass vial arm dendrimer (Cys containing sequence, 1.5 eq. per
chloroacetyl endgroup in core sequence) was weighed and
ushed with Ar during 10 min. The core dendrimer/KI solution
was transferred to the glass vial containing the arm dendrimer
via a gas-tight syringe. DIPEA (55 eq.) was added and the solu-
tion stirred overnight at room temperature under argon atmo-
sphere. The reaction was followed by analytical RP-UHPLC.
Aer 16 to 23 hours, the reaction was quenched by the addition
of 3.5 mL of eluent A (MilliQ deionized water containing 0.1%
TFA). Aer ltration, the solution was directly puried by
preparative RP-HPLC. x denotes the –CH2–CO– bridge between
the Cys side chain of the arm and the N-termini of the dendritic
cores. Yields are given for the chloroacetyl cysteine (ClAc) liga-
tion reaction.
FD2x. (cFuc-KPL)4(KFCxKI)2KHI was obtained as a foamy
white solid aer preparative RP-HPLC (7.9 mg, 2.05 mmol, 70%).
Analytical RP-UHPLC: tR ¼ 2.062 min (A/D 100/0 to 0/100 in 4.5
min, ow rate 1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for
C182H305N39O47S2 [M + H]
+: 3854.22, found: 3854.23.
GalAG2x. (GalA-KPL)4(KFCxKI)2KHI was obtained as a foamy
white solid aer preparative RP-HPLC (2.9 mg, 0.7 mmol, 24%).
Analytical RP-UHPLC: tR ¼ 2.087 min (A/D 100/0 to 0/100 in 4.5
min, ow rate 1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for
C202H313N39O55S2 [M + H]
+: 4230.24, found: 4231.24.
GalBG2x. (GalB-KPL)4(KFCxKI)2KHI was obtained as a foamy
white solid aer preparative RP-HPLC (3.8 mg, 0.9 mmol, 32%).
Analytical RP-UHPLC: tR ¼ 2.052 min (A/D 100/0 to 0/100 in 4.5178 | Chem. Sci., 2016, 7, 166–182min, ow rate 1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for
C186H313N39O51S6 [M + H]
+: 4102.15, found: 4103.15.
Het1G2. (cFuc-KPLK(Gal-KPL)FCxKI)2KHI was obtained as
a foamy white solid aer preparative RP-HPLC (10.3 mg, 2.55
mmol, 88%). Analytical RP-UHPLC: tR ¼ 2.065 min (A/D 100/0 to
0/100 in 4.5 min, ow rate 1.2 mLmin1, l¼ 214 nm). MS (ESI+)
calc. for C192H309N39O51S2 [M + H]
+: 4042.23, found: 1011.81 (z
¼ 4), 809.65 (z ¼ 5), 674.88 (z ¼ 6).
Het2G2. (GalA-KPLK(cFuc-KPL)FCxKI)2KHI was obtained as
a foamy white solid aer preparative RP-HPLC (9.3 mg, 2.3
mmol, 79%). Analytical RP-UHPLC: tR ¼ 2.075 min (A/D 100/0 to
0/100 in 4.5 min, ow rate 1.2 mLmin1, l¼ 214 nm). MS (ESI+)
calc. for C192H309N39O51S2 [M + H]
+: 4042.23, found: 4042.23.
Het3G2. (cFuc-KPLK(GalB-KPL)FCxKI)2KHI was obtained as
a foamy white solid aer preparative RP-HPLC (3.6 mg, 0.9
mmol, 31%). Analytical RP-UHPLC: tR ¼ 1.442 min (A/D 100/0 to
0/100 in 2.2 min, ow rate 1.2 mLmin1, l¼ 214 nm). MS (ESI+)
calc. for C184H309N39O49S4 [M + H]
+: 3978.19, found: 3978.18.
Het4G2. (GalB-KPLK(cFuc-KPL)FCxKI)2KHI was obtained as
a foamy white solid aer preparative RP-HPLC (7.3 mg, 1.84
mmol, 63%). Analytical RP-UHPLC: tR ¼ 1.425 min (A/D 100/0 to
0/100 in 2.2 min, ow rate 1.2 mLmin1, l¼ 214 nm). MS (ESI+)
calc. for C184H309N39O49S4 [M + H]
+: 3978.19, found: 3978.19 (z
¼ 1), 1991.10 (z ¼ 2).
Het5G2. (cFuc-KKLK(GalA-KKL)FCxKI)2KHI was obtained as
a foamy white solid aer preparative RP-HPLC (6.6 mg, 1.58
mmol, 54%). Analytical RP-UHPLC: tR ¼ 1.940 min (A/D 100/0 to
0/100 in 4.5 min, ow rate 1.2 mLmin1, l¼ 214 nm). MS (ESI+)
calc. for C196H329N43O51S2 [M + H]
+: 4166.40, found: 4166.40 (z
¼ 1), 1390.14 (z ¼ 3), 1042.86 (z ¼ 4), 834.49 (z ¼ 5), 695.57 (z ¼
6).
Het6G2. (GalA-KKLK(cFuc-KKL)FCxKI)2KHI was obtained as
a foamy white solid aer preparative RP-HPLC (7.1 mg, 1.7
mmol, 59%). Analytical RP-UHPLC: tR ¼ 1.938 min (A/D 100/0 to
0/100 in 4.5 min, ow rate 1.2 mLmin1, l¼ 214 nm). MS (ESI+)
calc. for C196H329N43O51S2 [M + H]
+: 4166.40, found: 4166.40.
Het7G2. (cFuc-KKLK(GalB-KKL)FCxKI)2KHI was obtained as
a foamy white solid aer preparative RP-HPLC (8.3 mg, 2.02
mmol, 69%). Analytical RP-UHPLC: tR ¼ 1.388 min (A/D 100/0 to
0/100 in 2.2 min, ow rate 1.2 mLmin1, l¼ 214 nm). MS (ESI+)
calc. for C188H329N43O49S4 [M + H]
+: 4102.36, found: 4102.36.
Het8G2. (GalB-KKLK(cFuc-KKL)FCxKI)2KHI was obtained as
a foamy white solid aer preparative RP-HPLC (6.8 mg, 1.66
mmol, 57%). Analytical RP-UHPLC: tR ¼ 1.912 min (A/D 100/0 to
0/100 in 4.5 min, ow rate 1.2 mLmin1, l¼ 214 nm). MS (ESI+)
calc. for C188H329N43O49S4 [M + H]
+: 4102.36, found: 4102.36.
AcG2x. (Ac-KPL)4(KFCxKI)2KHI was obtained as a foamy
white solid aer preparative RP-HPLC (4.8 mg, 1.47 mmol, 50%).
Analytical RP-UHPLC: tR ¼ 2.120 min (A/D 100/0 to 0/100 in 4.5
min, ow rate 1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for
C158H265N39O31S2 [M + H]
+: 3269.99, found: 3270.99.
AcG2xK. (Ac-KKL)4(KFCxKI)2KHI was obtained as a foamy
white solid aer preparative RP-HPLC (5.9 mg, 1.74 mmol, 60%).
Analytical RP-UHPLC: tR ¼ 1.953 min (A/D 100/0 to 0/100 in 4.5
min, ow rate 1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. for
C164H287N41O31S2 [M + H]
+: 3392.17, found: 3393.18.This journal is © The Royal Society of Chemistry 2016
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View Article OnlineChloroacetyl cysteine (ClAc) ligation of FucC6 and Le
a
A solution of core dendrimer (sequence containing chloroacetyl
endgroups), around 3 mg (1 eq.) and KI (20 eq.) in 130 mL of
H2O/MeCN (1 : 1, v/v) was prepared in a 5 mL pointed round-
bottom ask. The solution was degassed under high vacuum for
10 min and pressurized under Ar. In a second 5 mL pointed
round-bottom ask, peracetylated 6-mercaptohexyl-a-fucoside
or b-mercaptohexyl-Lewis A (10 eq.) and K2CO3 (0.3 eq.) were
loaded, degassed under high vacuum for 10 min, pressurized
under Ar, and dissolved in 200 mL of dry MeOH. The reaction
mixture was stirred for 1 hour at RT under an argon atmo-
sphere, which eﬀected complete deacetylation. The previously
prepared solution of the core dendrimer and DIPEA (55 eq.) was
then added to the reaction mixture which was stirred for 16 to
23 hours at RT under an argon atmosphere. The reaction was
followed by RP-UHPLC. Aer completion the reaction was
quenched by adding 10 mL of eluent A (MilliQ deionized water
containing 0.1% TFA) and directly puried by RP-HPLC. Yields
are given for the chloroacetyl cysteine (ClAc) ligation reaction.
FucC6G2. (FucC6-KPL)4(KKI)2KHI was obtained as a foamy
white solid aer preparative RP-HPLC (2.5 mg, 0.7 mmol, 31%).
Analytical RP-UHPLC: tR ¼ 1.553 min (A/D 100/0 to 0/100 in 2.2
min, ow rate 1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc. MS
(ESI+) calc. for C178H319N33O45S4 [M + H]
+: 3768.27, found:
3768.27.
LeaC6G2. (LeA-KPL)4(KKI)2KHI was obtained as a foamy
white solid aer preparative RP-HPLC (8 mg, 1.5 mmol, 63%).
Analytical RP-UHPLC: tR ¼ 2.137 min (A/D 100/0 to 0/100 in 4.5
min, ow rate 1.2 mL min1, l ¼ 214 nm). MS (ESI+) calc.
C234H411N37O85S4 [M + H]
+: 5228.80, found: 5228.80. [M + H +
TFA]+: 5342.80, found: 5342.78. [M + H + 2TFA]+: 5456.80, found
5457.78.Homodimerisation of Het2G1-Cys
G1 dendrimerHet2G1-Cys (4.5 mg, 1.0 eq.) was dissolved in 200
mL of degassed mQ-deionized water and ushed for 5 min with
argon. Then, Aldrithiol (2,2-dithiodipyridine) (45.5 mM in
MeOH, 0.45 eq.) was added. The thiol activation was followed by
analytical RP-HPLC. When the reaction was completed, MeOH
was evaporated and excess Aldrithiol was removed by extraction
with DCM (4 times, 300 mL). The water phase was transferred to
a new 5 mL pointed round-bottomed ask and ushed with Ar
for 5 min. The pH was then adjusted to 8–9 with (NH4)HCO3
buﬀer solution (400 mM). A second portion of the monomeric
dendrimer Het2G1-Cys (4.5 mg, 1.0 eq.) was added to the
reaction mixture. The reaction mixture was stirred for 18 hours
under argon at room temperature and followed by analytical RP-
HPLC. Aer completion of the reaction, the mixture was acidi-
ed with 3mL of water containing 0.1% of TFA. The homodimer
(Het2G1-Cys)2 was puried by preparative RP-HPLC.
(Het2G1-Cys)2. (GalA-KPLK(cFuc-KPL)FC)2 was obtained as
a foamy white solid aer preparative RP-HPLC (1.4 mg, 0.45
mmol, 7.1%). Analytical RP-UHPLC: tR¼ 3.009 min (A/D 100/0 to
0/100 in 7.5 min, ow rate 1.2 mLmin1, l¼ 214 nm). MS (ESI+)
calc. C146H228N26O42S2 [M + H]
+: 3083.69, found: 3084.60 (z¼ 1),
1028.54 (z ¼ 3), 771.66 (z ¼ 4).This journal is © The Royal Society of Chemistry 2016Isothermal titration calorimetry (ITC)
Recombinant PA-IIL was puried from Escherichia coli
BL21(DE3) containing the plasmid pET25pa2l as described
previously.50 Lyophilised LecB was dissolved in buﬀer (20 mM
Tris, 100 mM NaCl, 100 mM CaCl2, pH ¼ 7.5). Protein concen-
tration was checked and adjusted by measurement of absor-
bance at 280 nm using 1 Abs ¼ 0.576 mg mL1 (MW ¼ 11 863 g
mol1) using a NanoDrop instrument. Ligands were dissolved
using the same buﬀer. ITC were performed with iTC200 calo-
rimeter (MicroCal Inc.). Titration was performed on 0.028–0.50
mM LecB in the 200 mL sample cell using 2 mL injections of
ligand every 180 s at 25 C. The data were tted with MicroCal
Origin 8 soware, according to standard procedures using
a single-site model. Change in free energy DG was calculated
from the equation: DG ¼ DH  TDS where T is the absolute
temperature, DH and DS are the change in enthalpy and
entropy, respectively. Two independent titrations were per-
formed for each ligand tested. Eﬀective concentration has been
determined using a-Me-fucose, a high aﬃnity ligand that gives
precise determination of the stoichiometry in active sites. The
eﬀective concentration that has been determined for this batch
of LecB was of 70% (of mass concentration). The concentrations
of LecB were then corrected based on this value.
Recombinant PA-IL was puried from Escherichia coli
BL21(DE3) containing the plasmid pET25paIL as described previ-
ously.51 Lyophilised LecAwas dissolved in buﬀer (Tris 20mM,NaCl
100 mM, CaCl2 100 mM, pH ¼ 7.5). Protein concentration was
checked and adjusted by measurement of absorbance at 280 nm
using 1 Abs ¼ 2.116 mg mL1 (MW ¼ 12 893 g mol1) using
a NanoDrop instrument. Ligands were dissolved using the same
buﬀer. ITC were performed with iTC200 calorimeter (MicroCal
Inc.). Titration was performed on 0.0166–0.526 mM LecA in the
200 mL sample cell using 2 mL injections of 200 mM ligand every 120
s at 25 C. The data were tted with MicroCal Origin 8 soware,
according to standard procedures using a single-site model.
Change in free energy DG was calculated from the equation: DG¼
DH TDSwhere T is the absolute temperature, DH and DS are the
change in enthalpy and entropy, respectively. Two independent
titrations were performed for each ligand tested.Biolm inhibition and dispersal
Amodied version of the method described by Diggle et al.9 was
employed.31 96-well sterile, U-bottomed polystyrene microtiter
plates (TPP Switzerland) were prepared by adding 200 mL of
sterile deionized water to the peripheral wells to decrease
evaporation from test wells. Aliquots of 180 mL of culture
medium (0.25% (w/v) nutrient broth no. 2, Oxoid) containing
desired concentration of the test compound were added to the
internal wells. Compound containing solutions were sterile
ltered (pore size 0.22 mm) prior to addition to the wells. Inoc-
ulum of Pseudomonas aeruginosa strain PAO1 was prepared
from 5 mL overnight culture grown in LB broth at 37 C and 180
rpm shaking. Aliquots of 20 mL of overnight cultures, pre-
washed in 0.25% (w/v) nutrient broth and normalised to an
OD600 of 1, were inoculated into the test wells. Plates were
incubated in a humid environment for 24–25 hours at 37 CChem. Sci., 2016, 7, 166–182 | 179
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View Article Onlineunder static conditions. Wells were washed twice with 200 mL
sterile deionized water before staining with 200 mL 0.25% (w/v)
nutrient broth containing 0.5 mMWST-8 and 20 mM phenazine
ethosulfate for 2.5–3 hours at 37 C under static conditions.
Aerwards, the well supernatants were transferred to a poly-
styrene at bottomed 96-well plate (TPP Switzerland) and the
absorbance was measured at 450 nm with a plate reader
(SpectraMax250 from Molecular Devices).
For biolm dispersal, biolm was being formed as described
above but in the absence of compound for 24 hours. Wells were
washed twice with 200 mL sterile deionized water before adding
200 mL 0.25% (w/v) nutrient broth containing the desired
concentration of compound. Compound containing solutions
were sterile ltered (pore size 0.22 mm) prior to addition to the
wells. Aer another 24 hours of incubation at 37 C under static
conditions, the well supernatants were removed and the wells
were washed twice with 200 mL sterile deionized water. The bio-
lm was stained with 200 mL of 0.25% (w/v) nutrient broth con-
taining 0.5mMWST-8 and 20 mMphenazine ethosulfate for 2.5–3
hours at 37 C under static conditions. The resulting absorbance
was measured as in the biolm inhibition experiment.
Broth microdilution method
Glycopeptide dendrimers cytotoxicity was assayed against Pseu-
domonas aeruginosa PAO1. To determine the Minimal Inhibitory
Concentration (MIC), broth microdilution method was used. A
colony of bacteria from glycerol stock was grown in LB medium
overnight at 37 C and 180 rpm shaking. The compounds were
prepared as stock solutions of 64 mM in LBmedium, added to the
rst well of 96-well sterile, F-bottomed polystyrene microtiter
plates (TPP, untreated) and diluted serially by 1/2. Compound
containing solutions were sterile ltered (pore size 0.22 mm) prior
to addition to the wells. The concentration of the bacteria was
quantied by measuring absorbance at 600 nm and diluted to an
OD600 of 0.022 in LB medium. The sample solutions (150 mL)
were mixed with 4 mL diluted bacterial suspension with a nal
inoculation of about 5  105 CFU. For each test, two columns of
the plate were kept for sterility control (LB medium only), growth
control (LB medium with bacterial inoculum, no compound).
The positive control, polymyxin B (starting with a concentration
of 64 mg mL1) in LB medium with bacterial inoculums, was
introduced in the two rst lines of the plate. The plates were
incubated at 37 C for 18 hours under static conditions. 15 mL
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) (1 mg mL1 in sterilized milliQ deionized water) were
added to each well and the plates were incubated for 10 minutes
at room temperature. The minimal inhibitory concentration
(MIC) was dened as the lowest concentration of the glycopep-
tide dendrimer that inhibits the visible growth of the tested
bacteria (yellow) with the unaided eye. For broth microdilution
assay, polymyxin B was used as references.17
Quantication of bacterial cell viability in biolm inhibition
and dispersal assays
96-well sterile, U-bottomed polystyrene microtiter plates (TPP
Switzerland) were prepared by adding 200 mL of sterile180 | Chem. Sci., 2016, 7, 166–182deionized water to the peripheral wells to decrease evaporation
from test wells. Aliquots of 180 mL of culture medium (0.25% (w/
v) nutrient broth no. 2, Oxoid) containing desired concentration
of the test compound were added to the internal wells.
Compound containing solutions were sterile ltered (pore size
0.22 mm) prior to addition to the wells. Inoculum of Pseudo-
monas aeruginosa strain PAO1 was prepared from 5 mL over-
night culture grown in LB broth at 37 C and 180 rpm shaking.
Aliquots of 20 mL of overnight cultures, pre-washed in 0.25% (w/
v) nutrient broth and normalised to an OD600 of 1, were inoc-
ulated into the test wells. Plates were incubated in a humid
environment for 24–25 hours at 37 C under static conditions.
The supernatants were used to investigate the bacterial cell
viability by two diﬀerent methods: CFU plating and OD600
measurement.
For OD600 measurement, the 200 mL of the supernatant were
added to 5 mL of LBmedium and shaken at 37 C for 7–8 hours.
The OD600 wasmeasured with an Ultrospec 10 cell density meter
from GE Health Care Life Sciences and compared to the w/o
supernatant. For CFU plating, the supernatant was added to the
rst well of a 96-well sterile, F-bottomed microtiter plate (TPP,
untreated) and diluted serially by 1/2 (raw 1 to 6) in 180 mL NaCl
0.9%. 4 mL of raw 6 were plated on LB agar and incubated at 37
C for 24 hours under static conditions. Wells were washed
twice with 200 mL sterile deionized water before staining with
200 mL 0.25% (w/v) nutrient broth containing 0.5 mM WST-8
and 20 mM phenazine ethosulfate for 2.5–3 hours at 37 C under
static conditions. Aerwards, the well supernatants were
transferred to a polystyrene at bottomed 96-well plate (TPP
Switzerland) and the absorbance was measured at 450 nm with
a plate reader (SpectraMax250 from Molecular Devices).
For biolm dispersal, biolm was being formed as described
above but in the absence of compound for 24 hours. Wells were
washed twice with 200 mL sterile deionized water before adding
200 mL 0.25% (w/v) nutrient broth containing the desired
concentration of compound. Aer another 24 hours of incuba-
tion at 37 C under static conditions, the well supernatants were
used to check the bacterial cell viability by CFU plating and
OD600 measurement. For OD600 measurement, the 200 mL of the
supernatant were added to 5 mL of LB medium and shaken at
37 C for 7–8 hours. The OD600 was measured and compared to
the w/o supernatant. For CFU plating, the supernatant was
added to the rst well of a 96-well sterile, F-bottomed microtiter
plate (TPP, untreated) and diluted serially by 1/2 (raw 1 to 6) in
180 mL NaCl 0.9%. 4 mL of the raw 6 were plated on LB agar and
incubated at 37 C for 24 hours under static conditions. The
wells were washed twice with 200 mL sterile deionized water. The
biolm was stained with 200 mL of 0.25% (w/v) nutrient broth
containing 0.5 mMWST-8 and 20 mM phenazine ethosulfate for
2.5–3 hours at 37 C under static conditions. The resulting
absorbance was measured as in the biolm inhibition
experiment.Growth curve control studies
180 mL of LB medium were added to wells of a 96-well sterile, F-
bottomed polystyrene microtiter plate. Compound containingThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinesolutions were sterile ltered (pore size 0.22 mm) prior to
addition to the wells. An overnight culture of Pseudomonas
aeruginosa strain PA01 grown in LB was standardised to an
OD600 of 0.5 and 20 mL aliquots were inoculated into test wells.
The microtiter plate was shaken at 37 C and 180 rpm. Growth
was followed at several time points over a period of 24 hours
with a plate reader at 600 nm (SpectraMax250 from Molecular
Devices).Crystallization of Het1G1$LecB
LecB lectin was expressed, cleaned up and dialyzed as previ-
ously described.52 Co-crystallization of Het1G1 with LecB lectin
was carried out by the sitting drop method. In brief, lyophilized
protein was dissolved in water (5 mg mL1) in the presence of
salts (1 mM CaCl2 and MgCl2). The compound Het1G1 was
added to the LecB homo-tetramer at a 16 : 1 molar excess.
Crystals were obtained within ve days aer mixing 1.5 mL of
LecB ligand-complex with 1.5 mL of reservoir solution at 18 C.
Primary crystallization condition was found in Crystal Screens I/
II (Hampton Research, Laguna Niguel, CA, USA). Crystals of
highest diﬀraction were obtained from condition 0.1 M sodium
acetate trihydrate, 2 M sodium chloride pH 4.6, Crystal Screen
II-9. The structures were solved using the XDS,53 CCP4,54 the
phenix55 program suite and the coot56 graphical program.
Pictures were done with the help of pymol.Acknowledgements
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